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1. Introduction and Relevance
Infectious diseases and cancer are leading causes of mortality and our ability to combat
them is compromised due to the emergence of antibiotic-resistant strains of bacteria and
chemotherapy-resistant cancer cells. Combined with the scarcity of new classes of antibiotics
due to the abandonment of antibacterial research by pharmaceutical companies (Williams
and Bax, 2009) and the lengthy development time lines to market (Projan and Bradford,
2007), there is an urgent need for alternative therapeutics. Cationic antimicrobial peptides
(CAPs) have emerged as a promising source of novel therapeutics. Not only do they rapidly
kill microbes and cancer cells, they also can modulate host innate immunity to augment
clearance of microbes and promote tissue healing resulting from inflammation. Further‐
more, they are less prone to resistance than traditional antibiotics (McPhee and Hancock,
2005). Synthetic variants of naturally occurring CAPs, have been designed that exhibit great‐
er selectivity and stability. Here I summarize some of the key features of CAPs, directing the
reader to recent pertinent reviews, and focus on characteristics of pleurocidin CAPs that
make them attractive for clinical applications.
2. Physical properties of cationic antimicrobial peptides
2.1. Classes
CAPs are small peptides (10-50 amino acids) with a high content of positively charged (net
charge +2 to +9) and hydrophobic (up to 50%) amino acids. Currently over 1800 naturally
occurring CAPs from almost all forms of life are annotated in the Antimicrobial Peptide Da‐
tabase (http://aps.unmc.edu/AP/main.php). They can be classified into four structural
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groups: linear α-helical, β-sheet, loop, and extended structures enriched in certain amino
acids such as Arg, Phe, Pro, Gly, Trp and His (Zasloff, 2002). Linear α-helical CAPs such as
magainin, LL-37 and pleurocidin are usually unstructured in aqueous solution but adopt an
α-helical conformation upon interaction with lipids, thereby acquiring antimicrobial activi‐
ty. They often contain a hinge in the middle, due to Gly or Pro residues, which enhances the
ability of the peptide to enter the cell (Park et al., 2000). CAPs that form stable β-sheet struc‐
tures contain cysteine residues that are able to form disulphide bonds (usually 1-4 depend‐
ing on the type of CAP). These include the protegrins, defensins and drosomycins. Looped
CAPs, thanatin and brevinin, contain a C-terminal loop carrying a strong positive charge
(Fehlbaum et al., 1996). CAPs such as bactenecin, prophenin and indolicidin are enriched in
specific amino acids, usually lack cysteines, and form linear or extended coils. CAPs are usu‐
ally produced as inactive pre-pro-peptides and proteolytically cleaved to release the mature
biologically active peptide.
2.2. Pleurocidin
Pleurocidins comprise a family of linear α-helical CAPs consisting of a highly conserved
amino-terminal signal sequence and a carboxy-terminal anionic segment flanking the more
variable mature peptide of approximately 25 amino acids (Douglas et al., 2001; Patrzykat et
al., 2003). This anionic portion may counteract the positively charged mature peptide, there‐
by keeping it inactive until cleaved. They show some sequence similarity to other fish CAPs,
including piscidin, moronecidin and the recently discovered gaduscidin (Browne et al.,
2011; Sun et al., 2007). Pleurocidins are encoded as clusters of genes comprised of four
exons, and binding sites for transcription factors involved in host defense are located up‐
stream of the promoters (Douglas et al., 2003).
Pleurocidin variant NRC-04 is the best-studied of this family of peptides. Early studies
showed that in 25% dodecylphosphatidylcholine (DOPC)/ dodecylphosphatidyl-ethanola‐
mine (DOPE) vesicles, it forms a structure containing between 12% and 24% α-helical con‐
tent (Yoshida et al., 2001). Supporting this, it was only weakly incorporated into neutral
bilayers composed of a 7:3 mixture of DOPC and DOPE; however, it strongly associated
with a slightly anionic bilayer of 7:3:1 DOPC, DOPE, and dodecylphosphatidylserine
(DOPS), forming well-defined single ion channels (Saint et al., 2002). NMR studies have
shown that in 0% DPC, pleurocidin has no identifiable well-defined secondary structure but
in 30% TFE and in 10 mM DOPC micelles, it was 25% α-helical and this increased to 95% in
140 mM DOPC (Syvitski et al., 2005). The hydrophobic amino acids residues clustered on
approximately 2/3 of the helix and hydrophilic residues on the remaining 1/3 of the helix.
3. Distribution and expression of cationic antimicrobial peptides
3.1. Organismal distribution
CAPs are ubiquitous in nature and play a crucial role in first-line host defense against
pathogens. Fish and marine invertebrates, because of their diversity and reliance on non-
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specific innate immune defenses, have proved to be a particularly good source of novel
CAPs with therapeutic potential (Otero-González, 2010; Smith and Fernandes, 2009).
3.2. Expression
3.2.1. Tissue specificity
In mammals, CAPs are expressed in cells of the skin and mucosal surfaces, as well as blood
cells such as platelets, monocytes/macropages, neutrophils, and mast cells (Guaní-Guerra et
al., 2010). Tissues often express a cocktail of different CAPs with varying activities and the
expression of a given CAP variant may be restricted to a specific cell type (see Wiesner and
Vilcinskas, 2010). For example, of the six different α-defensins, four are produced predomi‐
nantly in neutrophils whereas two are secreted from Paneth cells of the small intestine.
Fish CAPs such as pleurocidin are expressed in a broad range of tissues and cell types in‐
cluding epithelial, immune and blood cells (Browne et al., 2011). Pleurocidin is produced by
epithelial cells of the skin and gut (Cole et al., 1997; Douglas et al., 2001) as well as circulat‐
ing immune cells (Murray et al., 2007). Interestingly, different pleurocidin variants are pro‐
duced by different cell types (Douglas et al., 2003), underscoring the importance of
screening multiple tissues to uncover the true diversity of CAPs.
3.2.2. Developmental stage
The presence of CAPs in neonates, who have yet to develop adaptive immunity, provides
enteric protection and impacts the composition of the commensal microflora. Milk lactofer‐
rin, from which the CAP lactoferricin is produced by pepsin cleavage in the stomach, plays
a major role in maternal and innate immunity (Jenssen and Hancock, 2009). Dermicidin
YP-30 is important for maternal and early post-natal protection (Wiesner and Vilcinskas,
2010). Mouse cathelin-related antimicrobial peptide undergoes a developmental switch from
constitutive intestinal epithelial expression in neonates to Paneth cell expression in adult in‐
testinal crypts (Menard et al., 2008).
Pleurocidin transcripts were detected early in development of winter flounder, when larvae
are most susceptible to pathogen-induced mortality, and showed a progressive increase as
development proceeded to adulthood (Douglas et al., 2001). Furthermore, different pleuroci‐
din variants were present at different stages of development, indicating that screening of
CAP production from various developmental stages of an organism is an excellent means of
discovering novel peptide variants.
3.2.3. Constitutive or inducible
CAPs may be expressed constitutively or inducibly in response to stress, poor nutrition, in‐
flammation (Wehkamp et al., 2003), injury or microbial infection (Redfern et al., 2011; Zasl‐
off, 2006), and exposure to environmental factors such as zinc (Talukder et al., 2011) or
vitamin D (White, 2010). For example, hCAP-18/LL-37 protein and mRNA expression was
up-regulated in neutrophils that had migrated to the inflamed gingival tissues of patients
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with chronic periodontitis (Turkoglu et al., 2011) and mycoplasma infection induces catheli‐
cidin expression in neutrophils of infected mice (Tani et al., 2011). Interestingly, increased
endogenous glucocorticoid levels induced by psychological stress reduce CAP expression in
mice, leading to increased susceptibility to infection (Aberg et al., 2007).
Expression of fish CAPs is also regulated in response to stress and disease (Douglas et al.,
2003a; Sun et al., 2007), and novel variants are often induced by such stressors. Monitoring
levels of CAPs in aquaculture settings provides early warning of immunosuppression due
to chronic stress, and conversely induction of CAPs provides protection against anticipated
stressful situations such as handling (Noga et al., 2011).
4. Mode of action of cationic antimicrobial peptides
4.1. Membrane effects
CAPs can cause lysis of biological membranes or cross membranes by spontaneous lipid-as‐
sisted translocation. The initial interaction is electrostatic between the cationic residues of
the peptide and the negatively charged constituents of the target cell, whether they are in an
outer bacterial envelope, a viral envelope or a eukaryotic cell membrane. Because of the high
proportion of uncharged zwitterionic lipids and sterols in normal eukaryotic membranes,
however, these membranes are not as susceptible as negatively charged bacterial mem‐
branes or cancer cell membranes, which contain elevated levels of negatively charged sialy‐
lated glycoproteins (van Beek et al., 1973), O-glycosylated mucins (Yoon et al., 1996) and
phosphatidylserine (Riedl et al., 2011).
Upon binding, the peptide assumes an amphipathic secondary structure that facilitates
membrane disruption. A number of mechanisms have been proposed including micelle for‐
mation by the carpet model (Shai, 2002) and pore formation by the barrel-stave and toroidal
pore models (Brogden, 2005; Hadley and Hancock, 2010). Additional variations on these ini‐
tial models for bacterial membrane interactions have been proposed including localized
membrane disorganization by the aggregate model (Hancock and Rozek, 2002), the forma‐
tion of disordered toroidal pores, charged lipid clustering, membrane thinning, electropora‐
tion, non-lytic membrane depolarization, anion carriers and oxidized lipid targeting
(Nguyen et al., 2011).
Pleurocidin has been proposed to act via the toroidal pore model, based on its interactions
with model membranes (Saint et al., 2002). This finding is supported by NMR studies that
show that in DOPC pleurocidin exists as a very large species, probably composed of 20-25
aggregating molecules (Syvitski et al., 2005), indicating that at high concentrations pleuroci‐
din forms pores within the membrane environment or disrupts the membrane by aggrega‐
tion. A more recent study proposed that CAPS similar to pleurocidin such as magainin 2
adopt a surface alignment in mixed zwitterionic/anionic membranes and forms disordered
toroidal pores (Leontiadou et al., 2006). The interaction of pleurocidin with the anionic lipid
phosphatidylglycerol (PG) rather than the zwitterionic lipid phosphatidylethanolamine (PE)
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in mixed membranes, resulting in disruption of membrane integrity, was confirmed using
NMR (Mason et al., 2006). Interestingly, the three His residues, which become protonated at
acidic pH, play no role in membrane disruption, most likely due to their position along the
spine of the helix where they would be unlikely to interact with lipid head groups.
The Gly13 residue in the middle of pleurocidin confers flexibility between a longer α-helix
at the amino terminus and a shorter α-helix at the carboxy terminus allowing it to interact
with the negatively charged phospholipid membranes (Yang et al., 2006). Replacing Gly13
with Ala removes this hinge region, resulting in a much higher α-helical content and loss of
cell selectivity. This analog is hemolytic and interacts with both negatively charged (mimick‐
ing bacterial and cancer cell membranes) and zwitterionic (mimicking erythrocyte and nor‐
mal mammalian cell membranes) phospholipids. Similarly, substitution of both Gly13 and
Gly17 by Ala results in a large increase in α-helicity and a correspondingly dramatic in‐
crease in hemolytic activity, indicating that the hinge region facilitates flexibility and confers
bacterial cell selectivity (Lim et al., 2004a). It is interesting that Gly13 is conserved in 15 of
the 26 identified pleurocidin variants whereas Gly17 is conserved in only 6, indicating that
Gly13 plays the more important role in peptide function.
Sterols are commonly found in eukaryotic but not bacterial cell membranes, and their pres‐
ence in anionic mixed membranes reduces the ability of pleurocidin to insert even though
the peptide maintains its α-helical configuration (Mason et al., 2007). Cholesterol, found in
membranes of higher eukaryotes, was shown to be more effective than ergosterol, common‐
ly found in those of fungi and certain protozoa, in reducing insertion of CAPs. These differ‐
ences in membrane sterol content explain the differential sensitivity of bacteria, lower
eukaryotes and higher eukaryotes to CAPs such as pleurocidin. Using a fluorescent mem‐
brane probe, pleurocidin has been shown to structurally perturb the plasma membrane of
the fungal pathogen Candida albicans (Jung et al., 2007), confirming earlier killing assay re‐
sults (Patrzykat et al., 2003).
Structural modelling predicted that only 12 of the 26 described pleurocidin variants formed
amphipathic α-helices and killing assays showed that these were cytotoxic to HL-60 human
leukemia cells, resulting in rapid and complete killing (Morash et al., 2011). Cell death was
non-apoptotic and probably occurred by the formation of ion channels that dissipated the
membrane potential and led to cell lysis. The active pleurocidin variants were the more highly
charged (>+6.5) members of the family; interestingly only one of them was also hemolytic. The
anti-cancer activities of two pleurocidin variants (NRC-03 and NRC-07) against breast can‐
cer cells involve binding to negatively charged cell-surface molecules (Hilchie et al., 2011).
4.2. Intracellular effects
A number of CAPs, when administered at low doses, are able to penetrate the bacterial
membrane and disrupt metabolic processes (see Marcos and Gandia, 2009; Nicolas, 2009).
CAPs can assume different structures whilst exerting their inhibitory effects. For example,
when bound to DNA, buforin II assumes an extended form whereas magainin and pleuroci‐
din assume an α-helical form and bind DNA less effectively (Lan et al., 2010). Combinations
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of CAPs that exert their effects on different targets may exhibit synergy, and provide more
potent killing activity.
Pleurocidin usually causes membrane disruption at high concentrations whereas at low con‐
centrations, it can translocate into the cytoplasm without causing cell lysis and exert its ef‐
fects intracellularly, inhibiting DNA, RNA and protein synthesis (Patrzykat et al., 2002). The
intracellular effect of pleurocidin NRC-03 has since been probed using zebrafish embryos,
and shown to target the mitochondria and generate superoxide (Morash et al., 2011). TU‐
NEL staining indicates that the DNA of some cells becomes degraded, whereas other cells
undergo rapid lysis and cell death without DNA fragmentation. Pleurocidin variants
NRC-03 and NRC-07 cause mitochondrial membrane damage and production of reactive
oxygen species (ROS) in MDA-MB-231 breast cancer cells (Hilchie et al., 2011).
4.3. Receptors and binding proteins
In most cases, killing is by nonreceptor-mediated mechanisms since all D-amino acid enan‐
tiomers are generally as active as the natural L-amino acid peptides. However, stereospecific
receptor-mediated translocation has been described (Nicolas, 2009) and some CAPs trans‐
duce their effects via signaling networks upon interaction with receptors. Quite a diversity
of receptors have been described, possibly reflecting the diversity in peptide structures. Up‐
take of apidaecin into Gram negative bacteria is proposed to by an energy-dependent mech‐
anism involving a permease or transporter (Castle et al., 1999). The detection of
peptide:receptor complexes is technically very difficult but some receptors have been identi‐
fied. For example, the outer membrane protein OprI from P. aeruginosa (Lin et al., 2010) and
the outer membrane lipoprotein Lpp in Enterobacteriaceae (Chang et al., 2012) have been
shown to serve as receptors for α-helical CAPs. Histatin 5 and some defensins bind Ssa1/2
proteins on the cell surface of C. albicans in order to exert their activity, and the potassium
transporter TRK1 is also required for histatin5 fungicidal activity (Vylkova et al., 2007). In
eukaryotic cells, formyl peptide receptor-like 1 (FPRL1) is used as a receptor for LL-37 to act
as a chemoattractant (Yang et al., 2000) and induce angiogenesis (Koczulla et al., 2003).
LL-37 has also been shown to mediate keratinocyte migration and cytokine release by trans‐
activation of the epidermal growth factor receptor (Tokumaru et al., 2005) and P2X7 recep‐
tor (Elssner et al., 2004), respectively. However, activation of receptors could be via CAP-
induced changes in membrane fluidity, ion transport and/or receptor aggregation (Braff et
al., 2005) rather than direct binding.
Activation of mast cells by pleurocidin is G protein-dependent and proposed to involve FPRL1
and G protein coupled receptor signaling pathway (Kulka, unpub). The observation that
pleurocidin can bind and activate FPRL1 has some important implications for human dis‐
ease. The FPRL1 receptor subtype is also a receptor for the bacterially-derived peptide fMLP
(N-formyl-L-methionyl-L-leucyl-L-phenylalanine)  making it  an important  innate  immune
receptor (Selvatici et al., 2006). FPRL1 activates key components of the innate immune sys‐
tem and is responsible for chemotactic responses, superoxide anion production and degranu‐
lation by neutrophils, macrophages and mast cells. FPRL function has been shown to be
important in chronic obstructive pulmonary disease (COPD) due to cigarette smoking (Car‐
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dini et al.,  2012). FPRL1 can also transactivate epidermal growth factor receptors (EGFR)
making them a potentially important target in lung cancer (Cattaneo et al., 2011).
5. Biological activities and therapeutic applications of cationic
antimicrobial peptides
5.1. Antibacterial
Because of their rapid, broad spectrum bactericidal action, potency, and low host cytotox‐
icity, CAPs have elicited much excitement as alternatives to current antibiotics, particular‐
ly in the fight against antibiotic-resistant pathogens (Nijnik and Hancock, 2009). CAPs can
cause bacterial cell death by disrupting the bacterial membrane, by entering the cell and
inhibiting intracellular targets, or by stimulating the immune system to eliminate an infec‐
tion. They can be used alone or together with other antibacterial agents, with which they
frequently synergize.
Pleurocidins show broad-spectrum antimicrobial activity at micromolar concentrations and
also show synergistic activity with several antibiotics (Cole et al., 2000; Douglas et al., 2003;
Patrzykat et al., 2003). In contrast to many CAPs, pleurocidin is insensitive to NaCl concen‐
trations up to 150 mM, and may therefore have application in relatively high-salt bodily flu‐
ids and in treatment of lung infections in patients with cystic fibrosis, who have even higher
NaCl content (Goldman et al., 1997).
Recent studies have shown that pleurocidin possesses considerable activity against oral mi‐
croorganisms growing both planktonically and as a biofilm, even in the presence of saliva
(Tao et al., 2011). Incorporation of a targeting moiety to pleurocidin NRC-04 has significant‐
ly increased its specificity towards S. mutans, the main cause of dental caries, relative to oth‐
er oral bacteria (Mai et al., 2011). Addition of 5 mM EDTA or 10 ppm sodium fluoride, two
compounds commonly used in oral treatments, resulted in increased killing of S. mutans. Re‐
placement of Ser14 by His improved the activity of the targeted peptide at low pH similar to
that found in the oral cavity, showing that this targeted pleurocidin has good potential as an
anticaries agent.
Foodborne infections, especially those of seafood are a major health problem, yet only one
CAP, nisin, has been approved by the FDA for use as a food preservative and it has only
limited activity against Gram-negative bacteria or fungi (Burrowes et al., 2004).
Pleurocidin was tested against Gram-positive and Gram-negative bacteria of interest in food
safety and shown to be highly effective against 17 of 18 strains, particularly the fish spoilage
bacterium Vibrio alginolyticus (Burrowes et al., 2004). In addition, it was active against the
yeasts S. cerevisiae and P. pastoris, and the mold P. expansum, but was not detrimental to hu‐
man red blood cells or intestinal epithelial cells, indicating that it would be safe to use as a
food preservative. Furthermore, since pleurocidin is produced naturally by an edible fish,
there are fewer concerns over its use in food preservation.
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5.2. Antifungal
The antifungal properties of CAPs have been recognized for some time (De Lucca and Walsh,
1999); however, it is only recently that the mechanism of action has been elucidated. While
some CAPs such as LL-37 kill fungal cells by lysing the cell membrane, others such as hista‐
tin and defensins 2 and 3 kill in an energy-dependent and salt-sensitive fashion without cell
lysis (den Hertog et al., 2005; Vylkova et al., 2007). Magainin 2 and dermaseptin S3(1-16) also
cross the cell membrane and interfere with DNA integrity (Morton et al., 2007a; Morton et al.,
2007b). Histatin 5, lactoferrin, arenicin-1 and several other CAPs inhibit mitochondrial respi‐
ration and induce the formation of ROS and subsequent apoptosis in C. albicans (Andres et al.,
2008; Cho and Lee, 2011b; Helmerhorst et al., 2001; Hwang et al., 2011a; Hwang et al., 2011b).
Attempts to improve antifungal activity of CAPs have resulted in structural analogs with in‐
creased selectivity towards fungi and less host cytotoxicity. Hydrophobicity was shown to
be a crucial factor in the antifungal activity of a series of CAP analogs against zygomycetes
vs ascomycetes (Jiang et al., 2008). Synthetic, non-peptidic analogs of naturally-occurring
CAPs have shown potent activity as anti-Candida agents against biofilms in the oral cavity,
and reduced mammalian cytotoxicity (Hua et al., 2010).
Pleurocidin also possesses activity against C. albicans (Cole et al., 2000; Douglas et al., 2003;
Patrzykat et al., 2003) and various derivatives truncated at the amino or carboxy-termini show
reduced hemolytic activity although they are generally less potent (Lee and Lee, 2010). Mod‐
ification of pleurocidin to decrease hydrophobicity and α-helicity also resulted in active peptides
with reduced hemolytic activity (Sung and Lee, 2008). A synthetic all-D amino acid entantiom‐
er of pleurocidin has also been designed that showed resistance to trypsin, plasmin and
carboxypeptidase B proteases in vitro with no loss in antifungal activity (Jung et al., 2007).
Pleurocidin induces ROS, oxidative stress, mitochondrial depolarization, caspase activation,
and apoptosis in C. albicans  with concomitant membrane phosphatidylserine externaliza‐
tion, cell shrinkage, DNA fragmentation and nuclear condensation (Cho and Lee, 2011a).
5.3. Antiviral
Enveloped viruses are often susceptible to attack by CAPs. Four different linear CAPs were
shown to inactivate vaccinia virus by removal of the outer membrane, thereby rendering the
inner membrane susceptible to neutralizing antibody against the exposed antigens (Dean et
al., 2010). Novel HIV-1-inhibitory peptides have recently been identified by screening the
APD Antimicrobial Peptide Database for CAPs with promising antiviral properties. This un‐
covered 30 candidate CAPs which, when synthesized and tested, resulted in 11 peptides
with EC50<10 μM against HIV-1 (Wang et al., 2010). Some CAPs are able to exert antiviral
effects by blocking cell surface receptors used for viral entry. For example, the polyphemu‐
sin analog T22 binds CXCR4 on T cells and prevents T cell line-tropic HIV-1 entry (Muraka‐
mi et al., 1997).
The antiviral activity of pleurocidin variants has been tested against vaccinia virus grown in
HeLa cells and four lead candidates were identified based on viral inhibition without HeLa
cytotoxicity at both high and low multiplicity of infection (MOI) (Johnston, pers. comm.). At
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the more biologically relevant low MOI, two peptides were inhibitory with an IC50< 1 μg/ml.
Further studies are required to determine the mechanism by which pleurocidin exerts its an‐
tiviral effect.
5.4. Anti-parasitic
The anti-parasitic properties of magainins and cecropins have been known for over twenty
years and have subsequently been reported for many other CAPs (Harrington, 2011; Mor,
2009). CAPs are able to traverse the membranes of parasite-infected erythrocytes and are
proposed to change the properties of the parasite cell membrane, cause membrane lysis, or
become internalized and interfere with biological processes. BMAP-28, BMAP-27 and the
less cytotoxic truncated derivative BMAP-18 have recently been shown to possess excellent
in vitro activity against Leishmania and African trypanosomes growing both in mammalian
cells and in cells of the insect vector (Haines et al., 2009; Lynn et al., 2011). Importantly,
BMAP-18 was also able to inhibit release of leukocyte LPS-induced TNF-α associated with
inflammation and cachexia in patients with sleeping sickness. Further in vivo studies of nat‐
urally-occurring and engineered CAPs are needed to demonstrate their potential in the
treatment of serious parasite diseases of humans.
Pleurocidin inhibited the bloodstream form of Trypanosoma brucei at low concentration but
was not effective against the procyclic culture form or the tsetse symbiont (Haines et al.,
2003).
5.5. Anticancer
In contrast to conventional chemotherapy drugs that target all actively proliferating cells,
CAPs can show selective cytotoxicity towards cancer cells including dormant, slow-grow‐
ing, and multidrug resistant cells (see Hoskin and Ramamoorthy, 2008)). Both apoptotic (Jin
et al., 2010) and non-apoptotic (Ceron et al., 2010; Hilchie et al., 2011; Morash et al., 2011)
mechanisms have been proposed. The α-helical CAP, temporin-1CEa, exhibits cytotoxicity
towards all of 12 tested human carcinoma cell lines in a concentration-dependent manner,
yet no significant cytotoxicity to normal human umbilical vein smooth muscle cells at con‐
centrations that showed potent antitumor activity (Wang et al., 2011). The basis for selectivi‐
ty is thought to be the presence of phosphatidylserine, which is exposed on non-apoptotic
tumor cells including malignant metastatic cells and primary cell cultures. Susceptibility of
metastatic cells suggests that CAPs may be useful in treating metastatic as well as primary
cancers (Riedl et al., 2011).
In addition to direct killing of cancer cells, CAPs can affect T-cell dependent tumor regula‐
tion. Recently, intratumoral administration of a lactoferricin derivative into lymphomas es‐
tablished in mice resulted in tumor necrosis, infiltration of inflammatory cells, and
regression of tumors. Transfer of spleen cells from treated mice provided long-term, specific
T cell-dependent immunity against the lymphoma, suggesting therapeutic vaccination
against cancer using CAPs may be possible (Berge et al., 2010). In contrast, LL-37 was able to
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induce apoptosis of T regulatory cells, thus inhibiting their immune suppressor activity and
thereby enhancing the anti-tumor response (Mader et al., 2011).
Pleurocidins selectively killed human leukemia cells at low concentrations (<32 μg/mL) (Mo‐
rash et al., 2011) as well as multiple breast cancer cell lines (Hilchie et al., 2011) by a predom‐
inantly membranolytic mechanism. Disruption of the cell membrane also augmented the
activity of the chemotherapeutic cisplatin, presumably by enhancing access to the nucleus.
Furthermore, when administered intratumorally into breast cancer xenografts in mice, pleu‐
rocidin inhibited tumor growth and induced tumor necrosis, while not causing observable
adverse effects on the mice (Hilchie et al., 2011). These advantageous properties indicate that
pleurocidins should be pursued as novel anticancer agents.
5.6. Immunomodulatory
CAPs show multiple activities associated with modulation of the immune system (Jenssen
and Hancock, 2010; Yeung et al., 2011) and have been postulated to represent an evolution‐
ary link bridging innate and adaptive immune responses (Selsted and Ouellette, 2005).
CAPs are directly chemotactic for immune cells and also stimulate chemokine and cytokine
secretion (Lai and Gallo, 2009). Some CAPs are able to boost protein antigens and vaccines
that have low immunogenicity by inducing proinflammatory cytokines such as TNF, IFN
and IL-1β (Kindrachuk et al., 2009; Mutwiri et al., 2007; Tavano et al., 2011), suggesting that
they would be good adjuvants (Huang et al., 2011; Li et al., 2008). CAPs play a critical role in
wound healing (Steinstraesser et al., 2008), promoting keratinocyte migration (Aung et al.,
2011a), re-epithelialization (Hirsch et al., 2009), deposition of extracellular matrix (Oono et
al., 2002), and angiogenesis (Koczulla et al., 2003). Human β-defensins and LL-37 are able to
stimulate mast cells, and recently the neuroendocrine CAP catestatin has been reported to
induce migration and degranulation of mast cells, release of lipid mediators and production
of cytokines and chemokines (Aung et al., 2011b). CAPs also show promise in counteracting
sepsis, a major cause of morbidity and mortality in hospitalized patients. For example, intra‐
peritoneal injection of LPS-sensitized mice with S-thanatin reduced serum endotoxin and
TNF-α levels, resulting in 100% survival (Wu et al., 2011).
Pleurocidin has a proinflammatory effect in fish cells in vitro, inducing expression of IL-1β
and COX-2 (Chiou et al., 2006). In addition, pleurocidin variant NRC-08, which has no anti‐
bacterial activity, induced the expression of the co-stimulatory marker CD40 as well as
IL-12p40, TNF, and TGF from mouse bone marrow-derived immature dendritic cells (Phil‐
lips, Lee & Douglas, pers. comm.). The potential immunomodulating effects of this particu‐
lar pleurocidin variant, which promotes the maturation of DCs, suggest that it could be
further explored as a candidate adjuvant for a Th1 response to vaccine antigens.
Pleurocidins activate human mast cells to release granule contents such as histamine and
proteases (Kulka, per. comm.) both of which are important in allergic inflammation and tis‐
sue hometostasis. Mast cells are critical regulators of the tissue microenvironment capable of
responding to many different stimuli including allergens and releasing a huge variety of
pro-inflammatory and immunomodulatory mediators. Interestingly, pleurocidin activation
of mast cells is unique from that of allergens. Allergens bind to and crosslink surface high
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affinity immunoglobulin E receptors (FcεRI), which activates increases in intracellular calci‐
um and initiates several signaling pathways. Whereas FcεRI activation results in degranula‐
tion, arachidonic acid metabolite release and pro-inflammatory mediator production,
pleurocidin activation of FPRL1 initiates degranulation and production of relatively small
amounts of chemokines. Furthermore, whereas FcεRI engagement does not activate mast
cell chemotaxis, pleurocidins modify adhesion via the fibronectin receptor (CD29) and pro‐
mote mast cell migration. This suggests that pleurocidins activate selective signaling path‐
ways in mast cells and may be useful tools in targeted mast cell-dependent therapy.
5.7. Cytotoxic
5.7.1. Hemolysis and host cell lysis
Although most CAPs are not hemolytic or cytolytic at the concentrations used for killing mi‐
crobes or cancer cells, some do exhibit that characteristic, melittin being the most notorious
(Tosteson et al., 1985). Magainin also forms pores in human cell membranes and enters the
cell within minutes, accumulating in the nucleus and mitochondrion (Imura et al., 2008). Bo‐
vine myeloid antimicrobial peptides BMAP-27 and BMAP-28 at 10 times minimal inhibitory
concentration (MIC) are toxic towards human erythrocytes and polymorphonuclear cells
and induce apoptosis in transformed cell lines and in vitro-activated lymphocytes at concen‐
trations near MIC (Risso et al., 1998). A recent high-throughput method to assess cytotoxici‐
ty of melittin and structural variants differing in hydrophobicity, amphipathicity and
helicity, showed it to be more sensitive than standard tests such as erythrocyte lysis and
MTT assay and holds promise for identifying CAP variants with non-hemolytic properties
(Walsh et al., 2011).
Hemolysis assays of 26 variants of pleurocidin showed that only one, a histidine-rich variant
NRC-19, showed any ability to lyse red blood cells up to a concentration of 128 μg/mL, well
above the concentrations required to kill bacterial and cancer cells (Morash et al., 2011). The
selectivity of these peptides indicates that they would be excellent candidates as antibacteri‐
al and anti-cancer agents.
5.7.2. Sepsis
While many CAPs can reduce sepsis, some actually exacerbate the problem. This is because
they are so effective at killing bacterial cells that they cause the release of endotoxin from
lysed cells, eliciting an excessive inflammatory response (Risso et al., 1998; Steinstraesser et
al., 2003).
Preliminary studies using a mouse cytokine array showed that pleurocidin variants NRC-03
and NRC-08 are able to repress LPS-induced TNF-α and IL-10 secretion from mouse
RAW264.7 macrophages, indicating that they may be considered for the control of sepsis
(Carroll, Patrzykat & Douglas, pers. comm.).
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6. Isolation and discovery of cationic antimicrobial peptides
6.1. Traditional biochemical purification
Standard biochemical techniques for isolation of small peptides have been used to isolate
CAPs from tissues, skin secretions and other biological fluids. Briefly, tissue lysates or fluids
are diluted in 0.1% trifluoroacetic acid (TFA) and extracted under ice-cold acid conditions.
After centrifugation, the acidic supernatant is loaded on a C18 column and the peptide elut‐
ed with increasing acetonitrile (5-80%) in 0.05% TFA. Those fractions with antimicrobial ac‐
tivity are pooled and further purified by reverse-phase HPLC with increasing acetonitrile
(5-55%) in 0.05% TFA. The material in absorbance peaks is then pooled, dried under vacuum
and reconstituted in MilliQ water for mass and sequence analysis using mass spectrometry
and automated Edman degradation.
Pleurocidin was originally isolated from homogenates of the skin and mucus secretions of
winter flounder using C18 chromatography followed by size fractionation on Sephadex
G-50 (Cole et al., 1997). Biologically active fractions were pooled and subjected to strong cat‐
ion exchange HPLC and then reversed phase HPLC.
6.2.Genomics approaches to antimicrobial peptide discovery
Once even a partial amino acid sequence of a CAP is known, genomic strategies can be em‐
ployed to identify and isolate DNA sequences encoding CAPs. This can involve screening of
cDNA and genomic libraries using oligonucleotide probes or amplification of CAP-encod‐
ing sequences from genomic or cDNA by PCR (Iwamuro and Kobayashi, 2010). CAP-encod‐
ing sequences can also be identified in genomic and EST sequencing databases by similarity
searching using bioinformatics search engines such as BLAST (Browne et al., 2011; Fer‐
nandes et al., 2010). Full-length cDNA sequences can then be obtained by 5’- and 3’-RACE.
The identification of 28 new human and 43 new mouse β-defensin genes was achieved using
a computational search tool to find conserved motifs in draft genome sequences (Schutte et
al., 2002).
Pleurocidin was originally cloned from cDNA and genomic libraries using degenerate oligo‐
nucleotide probes (Cole et al., 2000; Douglas et al., 2001) or PCR amplicons encoding indi‐
vidual pleurocidin variants (Douglas et al., 2003). Additional pleurocidin variants were
amplified by PCR from cDNA of different flatfish species using primers corresponding to
the conserved amino-terminal signal peptide and carboxy-terminal anionic propiece (Patr‐
zykat et al., 2003). At least 30 variants have now been cloned (Figure 3).
6.3. In silico discovery and rational peptide design
Various in silico methods have been used to rationally design CAPs and predict their biolog‐
ical activity (Hadley and Hancock, 2010). These include the use of artificial neural networks,
support vector machines and quantitative structure activity relationship (QSAR) modeling
(Fjell et al., 2011; Torrent et al., 2011). Combinatorial synthesis and high throughput peptide
synthesis using SPOT technology (Hilpert et al., 2007) together with a QSAR-based artificial
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neural network system (Fjell et al., 2009) have also been used to design active synthetic
CAPs. This approach, coupled with high-throughput screening assays using peptide arrays,
is invaluable for inexpensively generating large numbers of potential candidates for clinical
assessment (Cherkasov et al., 2009).
7. Production of cationic antimicrobial peptides
7.1. Peptide synthesis
Isolation of CAPs from the native producer is not feasible on the scale necessary for investi‐
gating therapeutic value and pharmaceutical potential. Therefore, CAPs are usually synthe‐
sized by standard solid-phase methods using 9-fluorenyl-methoxycarbonyl (F-moc)
protecting groups, cleaved from the resin with 95% trifluoroacetic acid, purified by reverse-
phase high performance liquid chromatography using an acetonitrile gradient, and the mass
is verified by mass spectrometry. Although synthesis of linear α-helical peptides is fairly
routine, good yields of CAPs that require cysteine oxidation to form the correct disulphide
bonding pattern are rarely obtained (Tay et al., 2011). Modifications such as carboxy-termi‐
nal amidation, biotinylation, fluorescent labeling, incorporation of D-amino acids, acylation,
etc. are available for synthetic peptides.
7.2. Fermentation
7.2.1. Bacteria
Production of CAPs in bacteria using recombinant technology, by definition, is a challenge
as they inhibit or kill the host bacteria and bacterial proteases can degrade them. Recombi‐
nant technology, particularly of tagged fusion peptides, has been used successfully to pro‐
duce high yields of pure CAP at relatively low cost (Ingham and Moore, 2007). Factors to be
considered include optimization of promoter sequence and codon usage from the source or‐
ganism to bacterial host, signal peptide, tag, fusion partner, ease and cost of cleavage, and
cost of subsequent purification steps. A recent approach involving secretion of the tagged
SUMO-CAP hybrid into the medium followed by removal of the mature CAP by sumoase
protease has been particularly successful in large-scale production of several CAPs (Bom‐
marius et al., 2010; Li et al., 2009). In general, production of α-helical CAPs without disulfide
bonds and easily cleavable from their fusion partner has proved to be the most straightfor‐
ward and cost-effective. A recent report of expression of human β-defensin 28 in E. coli is
encouraging, however (Tay et al., 2011). By using a construct with both a His-tag and mal‐
tose binding protein and including the site for cleavage by TeV, an inexpensive and efficient
protease for releasing the mature CAP, large-scale production of correctly folded defensin
was achieved.
Pleurocidin has been successfully expressed as a PurF fusion peptide in inclusion bodies,
generating milligram quantities of pure peptide (Bryksa et al., 2006). By incorporating
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(15NH4)2-SO4 as the sole nitrogen source in the growth medium, structural elucidation of the
uniformly 15N-labelled peptide by NMR was greatly facilitated (Syvitski et al., 2005).
7.2.2. Fungi
Fungi such as Saccharomyces cerevisiae and Pichia pastoris represent alternative systems for re‐
combinant expression of CAPs. P. pastoris is a methylotrophic yeast that is capable of pro‐
ducing 10-100 times more recombinant protein than S. cerevisiae. However, successful
production of small proteins less than 10 kDa in P. pastoris can be problematic due to low
expression, RNA instability or translational blocks. Low amounts (~1 mg/100 mL) of re‐
combinant cecropin were produced in P. pastoris (Jin et al., 2006), and recently, high-level
production (>200 mg/L) of active recombinant hPAB-β (Chen et al., 2011) and plectasin
(Zhang et al., 2011) was achieved in this system.
Production of pleurocidin was attempted using this system; however, no recombinant pep‐
tide was recovered, despite correct integration of the pleurocidin sequence into the yeast ge‐
nome and normal transcription (Burrowes et al., 2005).
7.2.3. Animal cells
Production of CAPs in animal cells has the advantage of accurate processing of the recombi‐
nant peptide and addition of post-translational modifications. However, there are few re‐
ports of CAP production using this approach. The insect cell/baculovirus system has been
used to produce recombinant human β-defensins (Feng et al., 2005) and biologically active
hepcidin was successfully expressed, processed and secreted in human embryonic kidney
cells (Wallace et al., 2006). The complete pleurocidin pre-pro-peptide gene was cloned into a
carp cell line under the control of the carp β-actin promoter. The precursor peptide was ex‐
pressed continuously for over two years and the mature peptide was secreted into the medi‐
um (Brocal et al., 2006).
7.3. Transgenic organisms
Early attempts were made to express CAPs in the milk of transgenic mice (Yarus et al.,
1996), tissues of catfish (Dunham et al., 2002), and leaves of tobacco (Yevtushenko et al.,
2005) and rice (Imamura et al., 2010); however, while the recombinant CAPs were able to
confer pathogen resistance to the host organism, these systems are not designed for large-
scale production of CAPs for human applications.
8. Modifications to enhance biological activity and stability
8.1. Amino acid substitutions, additions and deletions
Modification of the amino acid sequence of CAPs to change the charge, hydrophobicity and
bulkiness can have dramatic effects on their ability to interact with membranes and exert
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their biological activity. Amidation of the carboxy terminus usually results in enhanced ac‐
tivity by increasing the net positive charge but has a negligible effect on protease susceptibil‐
ity. On the other hand, N-terminal acetylation significantly increases resistance to
aminopeptidases but decreases antimicrobial activity (Nguyen et al., 2010). In general, high
hydrophobicity confers hemolytic and cytotoxic properties on CAPs (McPhee and Hancock,
2005). The effect of amino acid substitutions on antimicrobial vs hemolytic activity has been
comprehensively evaluated using a series of rationally designed CAPs of 20 amino acids
that differ in charge, polar angle, hydrophobicity and hydrophobic moment (Chou et al.,
2008). Increasing the His content of clavanin resulted in an acid-activated CAP that showed
enhanced activity against the caries-producing pathogen, S. mutans, at low pH (Li et al.,
2010). Substitution of Lys by His in a 15-mer CAP resulted in a peptide that was cationic on‐
ly in the acidic microenvironment found in tumors, and exhibited enhanced anti-tumor ac‐
tivity and reduced systemic toxicity (Makovitzki et al., 2009). Addition of hydrophobic
amino acids to the termini of CAPs can also increase potency, although reduced solubility
and increased production cost present important drawbacks (Hadley and Hancock, 2010).
Recent reports of a truncated frog gaegurin (Won et al., 2011b) and the naturally short bee
anoplin (Won et al., 2011a) CAPs emphasize the enhanced antimicrobial effects of such mod‐
ifications on bacteria and model membranes.
Naturally occurring pleurocidins have variable amino acid sequences that confer different
activities against microbes and cancer cells (Morash et al., 2011; Patrzykat et al., 2003). Align‐
ment of the amino acid sequences of the mature peptides revealed conserved positions that
could be of importance in bioactivity. For example, the highly conserved Gly13 residue in
the middle hinge region is important for α-helicity (Lim et al., 2004b) and the hydrophobic
amino acids in the N-terminal region are more crucial for antifungal activity than those in
the C-terminal region (Lee and Lee, 2010). Replacement of Ser14 by His improved the activi‐
ty of a targeted pleurocidin towards S. mutans at low pH, which is often found in the oral
cavity (Mai et al., 2011).
8.2. Non-natural amino acids and enantiomers
Replacement of L-amino acids by their D counterparts generally does not diminish biologi‐
cal activity but does confer protease resistance on the peptide (Lee and Lee, 2008; Park et al.,
2010). Retro-inversion, in which amino acid stereochemistry is changed as well as peptide
bond direction yielding isomers with similar side chain topology to the native peptide, has
generally met with limited success although partially modified retro-inverso peptides show
more promise (Fischer, 2003). Incorporation of non-natural amino acid analogs (Knappe et
al., 2010; Marsh et al., 2009) is also effective. Recently, a series of CAPs containing Tic-Oic
dipeptide analogues was developed to combat 11 potential bio-terrorism and drug-resistant
strains of bacteria (Venugopal, 2010). These CAPs were metabolically stable, potent, and
showed selectivity for bacterial relative to host cell membranes.
Replacement of L-Lys and L-Arg residues with D-Lys and D-Arg in pleurocidin conferred
resistance to digestion by trypsin but also abolished activity, presumably because the α-heli‐
cal structure was disrupted by the inclusion of just a subset of amino acids (Douglas, un‐
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pub.). In support of this, an all D-amino acid analog of pleurocidin showed proteolytic resistance
and double the antifungal (Jung et al., 2007) and antibacterial (Lee and Lee, 2008) potency.
Similarly, an all D-amino acid analog of pleurocidin NRC-03, showed improved activity against
breast cancer cells compared to the natural L-form peptide (Hilchie, Hoskin, unpub).
8.3. Peptidomimetics
Peptidomimetics such as β-peptides and peptoids have been designed that maintain the
amphiphilic structure and antimicrobial activity and are resistant to protease degradation;
these abiotic structures exhibit in vivo stability and enhanced bioavailability (Rotem and Mor,
2009; Scott et al., 2008). Synthetic mimics of antimicrobial peptides (SMAMPs) that adopt
amphiphilic secondary structures and possess potent and selective antimicrobial activity have
been inexpensively synthesized from small synthetic oligomers (Lienkamp et al., 2008; Scott
et al., 2008). Another novel technique is hydrocarbon stapling (Sa'adedin and Bradshaw, 2010)
in which an α-helical peptide is chemically modified to generate a relatively protease resist‐
ant, cell-permeable peptide that binds its target with increased binding affinity.
8.4. Acylation
Addition of fatty acid chains to the termini of CAPs can increase their antibacterial activity
or endow them with antifungal activity. Linear oligomers consisting of alternating un‐
charged and cationic Lys residues displayed varying degrees of antibacterial, antifungal and
hemolytic activity when they were N-acylated, depending on the length of the acyl group
and the different degrees of oligomerization that were induced (Shai et al., 2006). Addition
of fatty acids of increasing lengths to magainin increased the extent of oligomerization of the
resulting lipopeptide, and concurrently the antifungal activity.
8.5. Cyclisation
Cyclisation by, for example, disulfide bridge formation or head-to-tail backbone cyclization,
results in a more constrained peptide structure that is less susceptible to protease degrada‐
tion (Nguyen et al., 2010). Cyclisation of two cationic hexapeptides, including the active por‐
tion of lactoferricin, was found to be highly effective for both serum stability and
antimicrobial activity. Interestingly, disulfide cyclization resulted in more active peptides
while backbone cyclization resulted in more proteolytically stable peptides. The modifica‐
tions did not result in hemolytic activity, thereby making them attractive therapeutic candi‐
dates. Dendrimers of CAPs have enhanced ability to permeabilize membranes and are
stabler than monomeric forms (Pieters et al., 2009).
8.6. Targeted and hybrid peptides
One of the drawbacks of antibiotic use is the deleterious effect broad spectrum antibiotics
have on the normal microflora, which often allows opportunistic pathogens such as C. albi‐
cans and S. aureus to overgrow after treatment. Selectively targeted antimicrobial peptides
(STAMPs) can overcome this problem and can selectively kill the target species while leav‐
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ing the benign commensals largely unaffected. This effect was first demonstrated using a
STAMP consisting of a competence stimulating peptide (CSP) moiety targeting the caries-
causing pathogen Streptococcus mutans attached to a killing moiety derived from novispirin
G10 (Eckert et al., 2006). Incorporation of such a STAMP into an oral rinse resulted in reduc‐
tion in salivary S. mutans, plaque, lactic acid and enamel demineralization, suggesting fur‐
ther clinical evaluation is warranted (Sullivan et al., 2011). Targeting of tumor cells has also
been achieved and addition of the tumor-homing peptide bombesin to the amino terminus
of magainin 2 resulted in tenfold enhanced killing in vitro and decrease in the size of tumor
xenografts in mice (Liu et al., 2011).
We have used this approach to combine the minimal targeting portion of CSP with the kill‐
ing domain of pleurocidin variant NRC-04 to treat S. mutans in both planktonic and biofilm
conditions. The hybrid peptide was selectively active against S. mutans in the presence of
saliva and physiological or higher salt concentration and was non-hemolytic (Mai et al.,
2011). Furthermore, activity was augmented by a preventative dose of 1 mM NaF, a com‐
pound commonly used in oral care. The development of such targeted peptides paves the
way for their use as a probiotic treatment to prevent dental caries.
9. Advantages and limitations of cationic antimicrobial peptides
9.1. Bioactivity
CAPs exert rapid, broad spectrum, bactericidal activity at micromolar concentrations and
are valuable weapons in the fight against antibiotic-resistant microbes e.g. MRSA. In addi‐
tion, targeted CAPs may be used as probiotics to eradicate pathogenic bacteria while leaving
normal flora unaffected. Their ability to kill fungi, viruses and parasites is also beneficial
clinically. Many CAPs neutralize endotoxin and can be used to counteract sepsis or to en‐
hance host defenses through immunomodulatory effects. Increased innate clearance of mi‐
crobes results in less bacterial debris (van der Does et al., 2010) and ensuing inflammation
(Andra et al., 2006). Their application both in killing tumor cells and in enhancing host anti-
tumor responses is gaining momentum (Yeung et al., 2011).
9.2. Resistance
CAPs have a low propensity to induce microbial resistance, mainly due to their multiple tar‐
gets and mechanisms of action. CAPs are usually expressed in high concentrations only at
sites of infection; continuous exposure of microbes, which often leads to resistance, is there‐
fore minimized. In addition, cocktails of several different CAPs are often produced simulta‐
neously, leading to increased microbial killing.
Despite this, some reports on the emergence of resistance have appeared. These include re‐
duction in bacterial cell surface negative charge, secretion of exoproteases and induction of
transporters (see Nizet, 2006; Peschel and Sahl, 2006), all of which require significant expen‐
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diture of metabolic energy by the microbe. In most cases, the resistance that arises is very
low compared to conventional antibiotics.
In Gram negative organisms such as Salmonella and Pseudomonas, the PhoP-PhoQ two com‐
ponent sensor system has been shown to control resistance to aminoglycosides, polymyx‐
in B, and cationic antimicrobial peptides (Macfarlane et al.,  1999; Macfarlane et al.,  2000;
Groisman, 2001).  In Pseudomonas,  CAPs and the polymyxins are capable of inducing the
pmrA-pmr genes and the putative LPS modification operon, thus increasing resistance to
these  agents  (McPhee  et  al.,  2003).  The  homologous  basR-basS  system of  E.  coli  is  also
induced by exposure to sublethal concentrations of the proline-rich CAP, Bac7(1-35), sug‐
gesting that it  may also mediate resistance (Tomasinsig et al.,  2004).  Resistance to Gram
positive organisms such as Staphylococcus  is  mediated by the Aps three component sen‐
sor  system,  and  interestingly,  some  CAPs  are  inducers  of  this  system  (Li  et  al.,  2007).
Recently, additional resistance genes in other bacteria such as Clostridium difficile (McBride
and Sonenshein, 2011) and Vibrio (Shen et al., 2010) have been discovered, emphasizing the
importance of this phenomenon.
9.3. Cost
Solid phase peptide synthesis is expensive and companies seeking regulatory approval for
peptides in their pipelines require suppliers that adhere to good manufacturing practice
(GMP) regulations, which also adds to the cost. However, there have been many advances
in synthetic chemistry that have significantly reduced the cost of not only peptides but also
non-peptide mimics and peptoids, and the lower operating costs of suppliers in Asia has re‐
sulted in more affordable peptides (Eckert, 2011).
9.4. Stability
Although CAPs represent a promising class of therapeutics, they have several in vivo draw‐
backs such as salt inactivation, protease degradation, and poor bioavailability. As described
above, a number of approaches can be used to mitigate these limitations. Serum stability can
be overcome by cyclisation or incorporation of amino acid analogs and some CAPs, particu‐
larly those such as pleurocidin that originated from marine sources, are active at physiologi‐
cal salt concentrations (Mai et al., 2011; Patrzykat et al., 2003).
9.5. Side effects
Some CAPs exhibit in vivo toxicity and for others there are unknown toxicity profiles (see
section 5.7). Nephrotoxicity has been associated with polymixin cyclic peptides (Mogi and
Kita, 2009). Since some CAPs can stimulate growth factor receptors, induction of tumorigen‐
esis must be considered. Similarly, excessive release of histamine from mast cells must be
avoided to minimize adverse reactions.
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10.Clinical use and commercialization
10.1. Companies
A number of CAPs and synthetic CAP analogs such as pexiganan™ (magainin derivative),
omiganan™ (indolicidin derivative), novispirin™ (cathelicidin derivative) and iseganan™
(protegrin-1 derivative) are now in commercial development. Several recent reviews de‐
scribe the companies, their products and their progression through clinical trials (Eckert,
2011; Kindrachuk and Napper, 2010; Yeung et al., 2011; Zhang and Falla, 2010). Some candi‐
dates show great promise in the treatment of such disorders as HIV-associated oral candi‐
diasis, acne, wound infections, diabetic foot ulcers, and oral biofilms. However, the inability
to demonstrate advantage over existing therapeutics has resulted in failure of a number of
CAPs at Phase III clinical trials. As appropriate formulations, bioassays and endpoints are
established, the probability that these promising products will receive regulatory approval
will improve.
10.2. Formulations
Because of systemic toxicity and bioavailability issues as well as the diverse and complex
mechanisms of action, the majority of CAPs have been developed as topical formulations
e.g. for diabetic foot ulcers (Lipsky et al., 2008) and skin infections (Falla and Zhang, 2010 ).
Depending on the application, a number of different ways of formulating CAPs can be envi‐
sioned (Eckert, 2011). CAPs have been incorporated into lens preservation and artificial tear
solutions (Huang et al., 2005) and aerosols (Lange et al., 2001). Inclusion of CAPs in coatings
(Kazemzadeh-Narbat et al., 2010), polymers (Gao et al., 2011), hydrogels (Roy and Das,
2008), liposomes (Lange et al., 2001), micro- and nanoparticles (Bi et al., 2011; Garlapati et
al., 2011) and even chewing gum (Faraj et al., 2007) also represent promising formulations.
Long-term activity has been achieved by covalent immobilization of gramicidin A on func‐
tionalized gold surfaces and resulted in inhibition of Gram-positive and Gram-negative bac‐
teria and the yeast Candida albicans for up to 6 months as well as delayed development of
bacterial biofilm for 24 hours (Yala et al., 2011). Surface modifications by CAPs will be im‐
portant in preventing colonization of medical devices such as catheters and bioimplants.
CAPs can also be used in combination therapies with each other or with approved antibiot‐
ics. For example, cecropin B enhanced the activities of beta lactams in rat septic shock mod‐
els (Ghiselli et al., 2004). Cecropin A and magainin 2 administered together showed in vitro
synergy against S. aureus in a mouse sepsis model (Cirioni et al., 2006). Magainin 2 adminis‐
tered with vancomycin showed the highest efficacy in this model.
Pleurocidin showed synergistic activity with inducible histone peptides and lysozyme in a
salmonid in vivo infection model (Patrzykat et al., 2001). Studies with S. mutans showed that
the efficacy of a targeted pleurocidin was increased in the presence of EDTA and sodium
fluoride, two commonly used components of oral rinses (Mai et al., 2011).
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10.3. Targeted delivery
CAPs with cell-penetrating properties are under development as vectors for translocation of
bioactive cargos with inherently poor membrane-crossing abilities into eukaryotic cells
(Splith and Neundorf, 2011). Delivery of CAP-modified liposomes containing therapeutics
to bacteria has also been reported, e. g. bacteria-targeted delivery of photodynamic antimi‐
crobial chemotherapy to improve efficiency against MRSA and P. aeruguinosa in local infec‐
tions (Yang et al., 2011).
11.Conclusions
CAPs show exciting promise as novel therapeutic agents, particularly in the fight against an‐
tibiotic-resistant bacteria and cancer and as immunostimulants. However, translation to clin‐
ical use has been hampered by concerns over stability, cost, systemic administration, known
toxicity, and unknown long-term toxicity. The applications that show the most promise are
those involving topical applications, particularly in combination with established antibiot‐
ics. Deeper understanding of the varied mechanisms of action of these diverse peptides and
the production of cost-effective, stable, and highly selective CAPs will aid in bringing these
molecules closer to the clinic.
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